Investegate announcements from AstraZeneca PLC, Ultomiris approved in EU for gMG

Related Keywords

Milan , Lombardia , Italy , Japan , United States , United Kingdom , Massachusetts , China , Boston , Bonifati , Calabria , Portugal , Sweden , Ireland , Cambridge , Cambridgeshire , America , Swedish , Republic Of Ireland , Istituto Neurologico Carlo Besta , Marc Dunoyer , Adrian Kemp , Renato Mantegazza , National Organization For Rare Disorders , Department Of Neuroimmunology , European Commission , Alexion Pharmaceuticals Inc , Nasdaq , Astrazeneca , Committee For Medicinal Products Human , Investor Relations Team , National Institutes Of Neurological Disorders , York Academy Of Sciences , Medicinal Products , Human Use , Myasthenia Gravis Activities , Daily Living Profile , Neuromuscular Diseases , Neurologico Carlo Besta , Chief Executive Officer , Japanin August , North America , Myasthenia Gravis Foundation , America Clinical Classification Class , Astrazeneca Rare Disease , Alexion Pharmaceuticals , Rare Diseases , New York Academy , Myasthenia Gravis , Intern Med , Myasthenia Gravis Epidemiology , Northern Portugal , Frequency Estimates , Clinical Epidemiological Distribution , Muscle Nerve , European Product Information , Ocular Myasthenia Gravis , National Organization , Rare Disorders , Accessed March , Clinical Overview , Gravis Fact , National Institutes , Neurological Disorders , Efficacy Study , Adults With Generalized Myasthenia , Investegate Announcements , Investegate Company Announcements , Astrazeneca Plc , Egulatory News Service , Egulatory News Service And Regulatory , Ns ,